Published in JAMA on August 23, 2006
Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood (2011) 1.14
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: the Worcester Venous Thromboembolism Study. Circ Cardiovasc Qual Outcomes (2010) 0.82
Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration. Br J Pharmacol (2008) 0.79
Thromboembolism. BMJ Clin Evid (2011) 0.79
Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Deep Venous Thrombosis: An Interventionalist's Approach. Ochsner J (2014) 0.77
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost. JAMA (2006) 0.75
Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism. JAMA (2007) 0.75
Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism. JAMA (2007) 0.75
Clinical pearls in thrombosis and anticoagulation. Mayo Clin Proc (2009) 0.75
Fixed-dose, weight-adjusted, unfractionated heparin was as effective and safe as low-molecular-weight heparin for venous thromboembolism. ACP J Club (2007) 0.75
Commentary. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. Perspect Vasc Surg Endovasc Ther (2007) 0.75
Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag (2008) 0.75
New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo) (2012) 0.75
A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis. Indian J Hematol Blood Transfus (2015) 0.75
Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution's Experience. P T (2008) 0.75
Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism. JAMA (2007) 0.75
Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism. JAMA (2007) 0.75
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 7.39
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2005) 6.80
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med (2003) 3.96
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med (2004) 3.74
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc (2005) 3.07
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med (2004) 2.76
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol (2009) 2.58
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26
Associations of neighborhood problems and neighborhood social cohesion with mental health and health behaviors: the Multi-Ethnic Study of Atherosclerosis. Health Place (2008) 2.14
The association of race with frailty: the cardiovascular health study. Ann Epidemiol (2006) 2.11
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J (2002) 2.09
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Psychosocial factors and coronary calcium in adults without clinical cardiovascular disease. Ann Intern Med (2006) 2.06
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med (2008) 1.91
The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital. N Z Med J (2003) 1.91
Acculturation and socioeconomic position as predictors of coronary calcification in a multiethnic sample. Circulation (2005) 1.90
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 1.87
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation (2006) 1.86
Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke (2006) 1.86
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol (2004) 1.81
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med (2003) 1.75
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.74
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med (2007) 1.70
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol (2006) 1.67
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation (2014) 1.64
Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res (2008) 1.64
Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med (2004) 1.63
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation (2005) 1.63
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am (2005) 1.59
Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol (2012) 1.58
A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography. Ann Intern Med (2005) 1.57
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
Transitions in spousal caregiving. Gerontologist (2003) 1.54
Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol (2013) 1.54
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol (2013) 1.54
Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol (2005) 1.54
A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53